Hashwah et al. showed that IL-6 activates and induces the proliferation of a subset of DLBCL cells that express IL-6 receptors, indicating that the IL-6 pathway is vital in some DLBCL cases and TCZ reduces the growth of primary DLBCL cells or DLBCL cell lines in various therapeutic settings [16]. The gene discussed is IL6; the disease is diffuse large B-cell lymphoma.